Phase IIb
ARamachol™ for REsolution of STeatohepatitis (ARREST)
Study Arms
400mg; 600mg; Placebo
Treatment Plane
Once-daily tablet for 12 months and 3 months follow-up
No. of Subjects
N=247
Primary Endpoint
- Percent change in the liver triglycerides concentration measured by MRS
Secondary Endpoint
- Proportion in percentages of subjects with NASH Resolution — ballooning 0; inflammation 0 or 1 — without worsening of CRN Fibrosis Score
- Proportion in percentages of subjects with CRN Fribrosis Score Improvement without worsening of NASHProportion in percentages of subjects with CRN Fribrosis Score Improvement without worsening of NASH
More information about the ARREST study may be found on ClinicalTrials.gov (identifier: NCT02279524); this study has been completed
These results were presented during a Late Breaking Abstract Oral Session at The Liver Meeting® 2018 during the American Association for the Study of Liver Diseases (AASLD).